Bristol Myers Squibb and Novo Nordisk Comparative Revenue Analysis
Bristol Myers Squibb (BMY) continues to demonstrate stable revenue performance through its diversified portfolio of oncology, cardiovascular, and immunological treatments. The company is currently expanding its manufacturing footprint with a multi-billion dollar investment in Texas and recently received FDA accelerated approval for a multiple myeloma combination therapy. In contrast, Novo Nordisk (NVO) has experienced significant volatility driven by its GLP-1 weight-loss and diabetes portfolio. While the company saw a massive 32% revenue surge in Q1 2026 following the U.S. launch of Wegovy, subsequent quarters have faced headwinds from seasonal ordering patterns and price erosion. Despite beating estimates, Novo Nordisk's stock faced pressure due to these fluctuations and high concentration risk, as Ozempic and Wegovy account for approximately 70% of its total revenue.
Topics: FDA approval manufacturing investment pharmaceuticals quarterly earnings revenue analysis
Read the full article at Motley Fool
Part of the story Comparative Revenue Analysis of AbbVie and Bristol Myers Squibb (3 articles)